Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.4
5.2
Journals
Cancers
Special Issues
Monitoring Treatment Response of Biomarkers in Cancer
share announcement

Monitoring Treatment Response of Biomarkers in Cancer

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Biomarkers".

Deadline for manuscript submissions: closed (31 January 2024) | Viewed by 7683

Special Issue Editors

Prof. Dr. Stamatios E. Theocharis

E-Mail Website
Guest Editor
First Department of Pathology, School of Medicine, National and Kapodistrian University of Athens, 11527 Athens, Greece
Interests: cancer pathology; cancer biomarker; cancer diagnosis; cancer prognosis; nutritional intervention in cancer clinical and experimental studies
Special Issues, Collections and Topics in MDPI journals
Dr. Alexandros G. Sykaras

E-Mail Website
Guest Editor
First Department of Pathology, Medical School, National and Kapodistrian University of Athens,11527 Athens, Greece
Interests: cancer pathology; cancer biomarker; cancer diagnosis; cancer prognosis; cancer treatment

Special Issue Information

Dear Colleagues,

Cutting-edge cancer research focuses on the identification of biomarkers with diagnostic, prognostic, predictive and therapeutic utility. The development of accurate and robust cancer biomarkers is critical for precision diagnostics and personalized treatment. Monitoring biomarkers should be used to assess the efficiency of therapeutic interventions, allowing the early detection of response to therapy or treatment failure and disease progression/relapse. The detailed on-treatment monitoring of biomarkers is of utmost importance for personalized medicine.

This Special Issue focuses on biomarkers’ response to cancer treatment. Therefore, we invite author to submit original research and review papers that advance our knowledge in this field and contribute to the development of personalized therapeutic tools.

Articles discussing liquid-biopsy based biomarkers, on-treatment monitoring biomarkers of minimal residual disease and biomarkers of response to immune checkpoint inhibitors are particularly welcome.

We look forward to receiving your contributions.

Prof. Dr. Stamatios E. Theocharis
Dr. Alexandros G. Sykaras
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • cancer biomarker
  • cancer diagnosis
  • cancer prognosis
  • cancer treatment
  • response

Published Papers (6 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

15 pages, 3631 KiB  
Article
Precision Isolation of Circulating Leukemia Cells in Chronic Myelogenous Leukemia Patients Using a Novel Microfluidic Device and Its Clinical Applications
by Dongfang Ouyang, Ningxin Ye, Kun Yang, Yiyang Wang, Lina Hu, Shuen Chao, Mehmet Toner and Yonghua Li
Cancers 2023, 15(23), 5696; https://doi.org/10.3390/cancers15235696 - 03 Dec 2023
Viewed by 1161
Abstract
Chronic Myelogenous Leukemia (CML) is a prevalent hematologic malignancy characterized by the malignant transformation of myeloid cells and their proliferation in the peripheral blood. The management of CML poses significant challenges, particularly in detecting and eradicating minimal residual disease, which is crucial for [...] Read more.
Chronic Myelogenous Leukemia (CML) is a prevalent hematologic malignancy characterized by the malignant transformation of myeloid cells and their proliferation in the peripheral blood. The management of CML poses significant challenges, particularly in detecting and eradicating minimal residual disease, which is crucial for preventing relapse and improving survival outcomes. Traditional minimal residual disease detection methods, such as bone marrow aspiration, are invasive and have limitations which include the potential for sampling errors and false negatives. This study introduces a novel label-free microfluidic chip designed for the segregation and recovery of circulating leukemia cells, offering a non-invasive liquid biopsy approach with potential applications in precision medicine. Over July 2021 to October 2023, we recruited 56 CML patients across various disease stages and collected blood samples for analysis using our microfluidic device. The device demonstrated high efficacy in isolating circulating leukemia cells, with an optimal capture efficiency of 78% at a sample flow rate of 3 mL/h. Our results indicate that the microfluidic device can efficiently segregate and quantify circulating leukemia cells, providing a detailed understanding of CML progression and treatment response. The significant reduction in circulating leukemia cell counts in patients in complete remission highlights the device’s potential in monitoring treatment efficacy. Furthermore, the device’s sensitivity in detecting minimal residual disease could offer a more reliable prognostic tool for therapeutic decision-making in CML management. Full article
(This article belongs to the Special Issue Monitoring Treatment Response of Biomarkers in Cancer)
►▼ Show Figures

Figure 1

14 pages, 645 KiB  
Article
Cardiac Dose Predicts the Response to Concurrent Chemoradiotherapy in Esophageal Squamous Cell Carcinoma
by Yu-Chieh Ho, Yuan-Chun Lai, Hsuan-Yu Lin, Ming-Hui Ko, Sheng-Hung Wang, Shan-Jun Yang, Tsai-Wei Chou, Li-Chung Hung, Chia-Chun Huang, Tung-Hao Chang, Jhen-Bin Lin and Jin-Ching Lin
Cancers 2023, 15(18), 4580; https://doi.org/10.3390/cancers15184580 - 15 Sep 2023
Viewed by 722
Abstract
Definitive concurrent chemoradiation (CCRT) is the standard treatment for cervical esophageal cancer and non-surgical candidates. Initial treatment response affects survival; however, few validated markers are available for prediction. This study evaluated the clinical variables and chemoradiation parameters associated with treatment response. Between May [...] Read more.
Definitive concurrent chemoradiation (CCRT) is the standard treatment for cervical esophageal cancer and non-surgical candidates. Initial treatment response affects survival; however, few validated markers are available for prediction. This study evaluated the clinical variables and chemoradiation parameters associated with treatment response. Between May 2010 and April 2016, 86 completed CCRT patients’ clinical, dosimetric, and laboratory data at baseline and during treatment were collected. Cox regression analysis assessed the risk factors for overall survival (OS). A receiver operating characteristic curve with Youden’s index was chosen to obtain the optimal cut-off value of each parameter. Treatment response was defined per Response Evaluation Criteria in Solid Tumors v.1.1 at the first post-CCRT computed tomography scan. Responders had complete and partial responses; non-responders had stable and progressive diseases. Logistic regression (LR) was used to evaluate the variables associated with responders. The Cox regression model confirmed the presence of responders (n = 50) vs. non-responders (n = 36) with a significant difference in OS. In multivariate LR, cardiac dose–volume received ≥10 Gy; the baseline hemoglobin level, highest neutrophil to lymphocyte ratio during CCRT, and cumulative cisplatin dose were significantly associated with the responders. The initial clinical treatment response significantly determines disease outcome. Cardiac irradiation may affect the treatment response. Full article
(This article belongs to the Special Issue Monitoring Treatment Response of Biomarkers in Cancer)
►▼ Show Figures

Figure 1

16 pages, 986 KiB  
Article
Enhancing Prediction for Tumor Pathologic Response to Neoadjuvant Immunochemotherapy in Locally Advanced Esophageal Cancer by Dynamic Parameters from Clinical Assessments
by Xin-Yun Song, Jun Liu, Hong-Xuan Li, Xu-Wei Cai, Zhi-Gang Li, Yu-Chen Su, Yue Li, Xiao-Huan Dong, Wen Yu and Xiao-Long Fu
Cancers 2023, 15(17), 4377; https://doi.org/10.3390/cancers15174377 - 01 Sep 2023
Viewed by 1036
Abstract
To develop accurate and accessible prediction methods for assessing pathologic response following NICT prior to surgery, we conducted a retrospective study including 137 patients with esophageal squamous cell carcinoma (ESCC) who underwent surgery after two cycles of NICT between January 2019 and March [...] Read more.
To develop accurate and accessible prediction methods for assessing pathologic response following NICT prior to surgery, we conducted a retrospective study including 137 patients with esophageal squamous cell carcinoma (ESCC) who underwent surgery after two cycles of NICT between January 2019 and March 2022 at our center. We collected clinical parameters to evaluate the dynamic changes in the primary tumor. Univariate and multivariate analyses were performed to determine the correlations between these parameters and the pathologic response of the primary tumor. Subsequently, we constructed prediction models for pCR and MPR using multivariate logistic regression. The MPR prediction Model 2 was internally validated using bootstrapping and externally validated using an independent cohort from our center. The univariate logistic analysis revealed significant differences in clinical parameters reflecting tumor regression among patients with varying pathologic responses. The clinical models based on these assessments demonstrated excellent predictive performance, with the training cohort achieving a C-index of 0.879 for pCR and 0.912 for MPR, while the testing cohort also achieved a C-index of 0.912 for MPR. Notably, the MPR prediction Model 2, with a threshold cut-off of 0.74, exhibited 92.7% specificity and greater than 70% sensitivity, indicating a low rate of underestimating residual tumors. In conclusion, our study demonstrated the high accuracy of clinical assessment-based models in pathologic response prediction, aiding in decision-making regarding organ preservation and radiotherapy adjustments after induction immunochemotherapy. Full article
(This article belongs to the Special Issue Monitoring Treatment Response of Biomarkers in Cancer)
►▼ Show Figures

Figure 1

Review

Jump to: Research

27 pages, 2598 KiB  
Review
Measurable (Minimal) Residual Disease in Myelodysplastic Neoplasms (MDS): Current State and Perspectives
by Linsheng Zhang, George Deeb, Kristin K. Deeb, Colin Vale, Deniz Peker Barclift and Nikolaos Papadantonakis
Cancers 2024, 16(8), 1503; https://doi.org/10.3390/cancers16081503 - 15 Apr 2024
Viewed by 392
Abstract
Myelodysplastic Neoplasms (MDS) have been traditionally studied through the assessment of blood counts, cytogenetics, and morphology. In recent years, the introduction of molecular assays has improved our ability to diagnose MDS. The role of Measurable (minimal) Residual Disease (MRD) in MDS is evolving, [...] Read more.
Myelodysplastic Neoplasms (MDS) have been traditionally studied through the assessment of blood counts, cytogenetics, and morphology. In recent years, the introduction of molecular assays has improved our ability to diagnose MDS. The role of Measurable (minimal) Residual Disease (MRD) in MDS is evolving, and molecular and flow cytometry techniques have been used in several studies. In this review, we will highlight the evolving concept of MRD in MDS, outline the various techniques utilized, and provide an overview of the studies reporting MRD and the correlation with outcomes. Full article
(This article belongs to the Special Issue Monitoring Treatment Response of Biomarkers in Cancer)
►▼ Show Figures

Figure 1

34 pages, 2351 KiB  
Review
The Clinical Impact of Death Domain-Associated Protein and Holliday Junction Recognition Protein Expression in Cancer: Unmasking the Driving Forces of Neoplasia
by Alexandros Pergaris, Ioannis Genaris, Ioanna E. Stergiou, Jerzy Klijanienko, Stavros P. Papadakos and Stamatios Theocharis
Cancers 2023, 15(21), 5165; https://doi.org/10.3390/cancers15215165 - 26 Oct 2023
Viewed by 1201
Abstract
Death domain-associated protein (DAXX) and Holliday junction recognition protein (HJURP) act as chaperones of H3 histone variants H3.3 and centromere protein A (CENPA), respectively, and are implicated in many physiological processes, including aging and epigenetic regulation, by controlling various genes’ transcription and subsequently [...] Read more.
Death domain-associated protein (DAXX) and Holliday junction recognition protein (HJURP) act as chaperones of H3 histone variants H3.3 and centromere protein A (CENPA), respectively, and are implicated in many physiological processes, including aging and epigenetic regulation, by controlling various genes’ transcription and subsequently protein expression. Research has highlighted both these biomolecules as participants in key procedures of tumorigenesis, including cell proliferation, chromosome instability, and oncogene expression. As cancer continues to exert a heavy impact on patients’ well-being and bears substantial socioeconomic ramifications, the discovery of novel biomarkers for timely disease detection, estimation of prognosis, and therapy monitoring remains of utmost importance. In the present review, we present data reported from studies investigating DAXX and HJURP expression, either on mRNA or protein level, in human tissue samples from various types of neoplasia. Of note, the expression of DAXX and HJURP has been associated with a multitude of clinicopathological parameters, including disease stage, tumor grade, patients’ overall and disease-free survival, as well as lymphovascular invasion. The data reveal the tumor-promoting properties of DAXX and HJURP in a number of organs as well as their potential use as diagnostic biomarkers and underline the important association between aberrations in their expression and patients’ prognosis, rendering them as possible targets of future, personalized and precise therapeutic interventions. Full article
(This article belongs to the Special Issue Monitoring Treatment Response of Biomarkers in Cancer)
►▼ Show Figures

Figure 1

11 pages, 1481 KiB  
Review
Assessment of Barriers and Challenges to Screening, Diagnosis, and Biomarker Testing in Early-Stage Lung Cancer
by Reza Zarinshenas, Arya Amini, Isa Mambetsariev, Tariq Abuali, Jeremy Fricke, Colton Ladbury and Ravi Salgia
Cancers 2023, 15(5), 1595; https://doi.org/10.3390/cancers15051595 - 03 Mar 2023
Cited by 6 | Viewed by 2484
Abstract
Management of lung cancer has transformed over the past decade and is no longer considered a singular disease as it now has multiple sub-classifications based on molecular markers. The current treatment paradigm requires a multidisciplinary approach. One of the most important facets of [...] Read more.
Management of lung cancer has transformed over the past decade and is no longer considered a singular disease as it now has multiple sub-classifications based on molecular markers. The current treatment paradigm requires a multidisciplinary approach. One of the most important facets of lung cancer outcomes however relies on early detection. Early detection has become crucial, and recent effects have shown success in lung cancer screening programs and early detection. In this narrative review, we evaluate low-dose computed tomography (LDCT) screening and how this screening modality may be underutilized. The barriers to broader implementation of LDCT screening is also explored as well as approaches to address these barriers. Current developments in diagnosis, biomarkers, and molecular testing in early-stage lung cancer are evaluated as well. Improving approaches to screening and early detection can ultimately lead to improved outcomes for patients with lung cancer. Full article
(This article belongs to the Special Issue Monitoring Treatment Response of Biomarkers in Cancer)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-6
Back to TopTop